Oppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price Target

Trevena, Inc. (NASDAQ:TRVN) received a $5.00 price target from equities researchers at Oppenheimer Holdings, Inc. in a note issued to investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 153.81% from the stock’s current price.

Other analysts have also recently issued research reports about the company. HC Wainwright decreased their target price on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday. Cowen and Company reaffirmed a “buy” rating and issued a $10.00 target price on shares of Trevena in a research report on Friday, August 4th. Finally, Zacks Investment Research cut Trevena from a “hold” rating to a “sell” rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company. Trevena has a consensus rating of “Buy” and an average target price of $10.23.

Trevena (TRVN) traded down 16.88% during trading on Thursday, reaching $1.97. The company had a trading volume of 3,936,648 shares. The stock has a 50 day moving average price of $2.49 and a 200 day moving average price of $2.75. The firm’s market capitalization is $117.60 million. Trevena has a 12 month low of $1.84 and a 12 month high of $8.00.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). On average, equities research analysts predict that Trevena will post ($1.41) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Oppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price Target” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2956049/oppenheimer-holdings-inc-analysts-give-trevena-inc-trvn-a-5-00-price-target.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its position in Trevena by 0.5% during the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 500 shares during the last quarter. American International Group Inc. boosted its position in Trevena by 7.1% during the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,816 shares during the last quarter. Teachers Advisors LLC boosted its position in Trevena by 6.2% during the fourth quarter. Teachers Advisors LLC now owns 77,523 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 4,505 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Trevena by 12.1% during the first quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 6,402 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Trevena by 30.1% during the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 14,880 shares during the last quarter. 60.09% of the stock is owned by hedge funds and other institutional investors.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.